Business
BioRestorative develops therapeutic products using cell and tissue protocols, including BRTX-100 for disc and spine conditions, plus a commercial biocosmeceuticals product.
BioRestorative Therapies had only $0.4M of FY2025 revenue, a $14.2M net loss, and severe equity erosion despite clean Beneish results.
The read at a glance✓ Audited against SEC data
- Business mix — Cell therapy and biocosmeceuticalsNote
- Revenue — $0.4M, -10.3%Watch
- Net income — -$14.2MWatch
- FCF — -$10.9MWatch
- Equity — $0.4M, -95.8%Watch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman distress; Beneish clean; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as BioRestorative Therapies, Inc. reports it. History and quarterly detail are in the app.
- Product$300K
- Royalty$60K
Leadership changes
From BioRestorative Therapies, Inc.'s own filings, the day they're filed.
- Steven Brown · director · departureeff. 2026-07-14
- Esha Randhawa · director · departureeff. 2026-07-13
- Katharyn Field · an officer · appointmenteff. 2026-07-13
Latest filings
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-08-25
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-07-16
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BioRestorative Therapies, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.